Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-an
![Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study - ScienceDirect Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0302283822025544-gr1.jpg)
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study - ScienceDirect
![Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER - European Journal of Cancer Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER - European Journal of Cancer](https://www.ejcancer.com/cms/asset/6e348d9e-fe9b-4434-bcdd-024b6b770d67/gr1.jpg)
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER - European Journal of Cancer
![Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study - European Urology Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study - European Urology](https://www.europeanurology.com/cms/asset/81f18467-6fce-4034-916c-218ba81825cf/gr2.jpg)